| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Canocapavir targets the HBV capsid protein, which is essential for viral replication. By modulating the capsid protein, the compound induces conformational changes in the linker region of the HBV core protein. This disrupts proper capsid assembly, thereby inhibiting HBV replication. The compound has oral antiviral activity.
|
|---|---|
| ln Vitro |
In vitro, Canocapavir has antiviral activity against HBV. Specific IC50 values for its antiviral activity are not provided in the available sources. Its activity is characterized in cell-based assays measuring HBV replication and capsid assembly.
|
| ln Vivo |
In vivo, Canocapavir has oral antiviral activity. It is being studied for the treatment of chronic hepatitis B. Specific in vivo efficacy data, such as effects on viral load in animal models, are not provided in the available sources.
|
| Enzyme Assay |
A cell-free assay for Canocapavir would involve measuring its binding to the HBV capsid protein or its ability to disrupt capsid assembly. These assays use purified capsid protein and assess the effects of the compound on capsid formation using biophysical methods. Specific protocols are not detailed.
|
| Cell Assay |
Cellular assays for Canocapavir typically involve assessing its antiviral activity against HBV in infected cell lines. Cells are treated with the compound, and HBV replication is measured by quantifying viral DNA, RNA, or antigens. The compound's ability to inhibit capsid assembly can also be assessed.
|
| Animal Protocol |
In vivo animal experiments for Canocapavir are not described in the available sources. As an orally active HBV inhibitor, it could be evaluated in animal models of HBV infection, such as humanized mouse models. However, no specific protocols or data are provided.
|
| ADME/Pharmacokinetics |
Canocapavir is an orally active compound. Specific pharmacokinetic parameters, such as half-life and bioavailability, are not provided in the available sources. The compound is being studied for the treatment of chronic hepatitis B.
|
| Toxicity/Toxicokinetics |
Toxicity data for Canocapavir are not provided in the available sources. As a research compound, it is intended for research use only and not for human consumption. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
Canocapavir (CAS: 2137847-19-7) is an orally available HBV capsid protein modulator with antiviral activity. It is also known as ZM-H1505R. The compound induces conformational changes in the HBV core protein and can be used for the treatment of chronic hepatitis B. It is not an approved drug and is strictly for research purposes.
|
| Molecular Formula |
C27H21BRFN5O3
|
|---|---|
| Molecular Weight |
562.389748334885
|
| Exact Mass |
561.081
|
| CAS # |
2137847-19-7
|
| Related CAS # |
(S)-Canocapavir;2137847-77-7
|
| PubChem CID |
137477479
|
| Appearance |
White to off-white solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
837
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1(=O)NC2=CC=C(CCN3C(=O)CO[C@@H]3C3=CN(C4=CC=C(Br)C=C4)N=C3C3=CC=C(F)C=C3)C=C2N1
|
| InChi Key |
YGPZZDKSASSELG-AREMUKBSSA-N
|
| InChi Code |
InChI=1S/C27H21BrFN5O3/c28-18-4-8-20(9-5-18)34-14-21(25(32-34)17-2-6-19(29)7-3-17)26-33(24(35)15-37-26)12-11-16-1-10-22-23(13-16)31-27(36)30-22/h1-10,13-14,26H,11-12,15H2,(H2,30,31,36)/t26-/m1/s1
|
| Chemical Name |
(2R)-2-[1-(4-bromophenyl)-3-(4-fluorophenyl)pyrazol-4-yl]-3-[2-(2-oxo-1,3-dihydrobenzimidazol-5-yl)ethyl]-1,3-oxazolidin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~300 mg/mL (~533.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 7.5 mg/mL (13.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 7.5 mg/mL (13.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7781 mL | 8.8906 mL | 17.7813 mL | |
| 5 mM | 0.3556 mL | 1.7781 mL | 3.5563 mL | |
| 10 mM | 0.1778 mL | 0.8891 mL | 1.7781 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
